Wall Street brokerages forecast that Akari Therapeutics PLC (NASDAQ:AKTX) will report earnings of ($1.00) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Akari Therapeutics’ earnings. Akari Therapeutics reported earnings of ($0.08) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 1,150%. The firm is scheduled to announce its next quarterly earnings report on Friday, March 30th.

According to Zacks, analysts expect that Akari Therapeutics will report full-year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($1.55). For the next year, analysts anticipate that the company will report earnings of ($3.00) per share. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Akari Therapeutics.

A number of equities research analysts recently issued reports on the stock. ValuEngine raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Zacks Investment Research upgraded Akari Therapeutics from a “sell” rating to a “hold” rating and set a $5.00 price objective on the stock in a report on Monday, November 13th. Canaccord Genuity restated a “buy” rating and issued a $15.00 price objective on shares of Akari Therapeutics in a report on Friday, September 22nd. William Blair upgraded Akari Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Finally, Chardan Capital restated a “neutral” rating on shares of Akari Therapeutics in a report on Sunday, September 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Akari Therapeutics currently has an average rating of “Hold” and an average target price of $7.50.

Shares of Akari Therapeutics (NASDAQ:AKTX) opened at $4.06 on Friday. Akari Therapeutics has a one year low of $3.18 and a one year high of $22.20. The stock has a market cap of $61.94, a price-to-earnings ratio of -1.51 and a beta of -8.64.

An institutional investor recently raised its position in Akari Therapeutics stock. VHCP Management II LLC raised its position in Akari Therapeutics PLC (NASDAQ:AKTX) by 15.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 426,297 shares of the biopharmaceutical company’s stock after purchasing an additional 56,807 shares during the period. Akari Therapeutics accounts for approximately 0.8% of VHCP Management II LLC’s portfolio, making the stock its 13th biggest holding. VHCP Management II LLC owned approximately 3.62% of Akari Therapeutics worth $1,965,000 at the end of the most recent quarter. 20.95% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/12/zacks-brokerages-anticipate-akari-therapeutics-plc-aktx-will-announce-earnings-of-1-00-per-share.html.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Get a free copy of the Zacks research report on Akari Therapeutics (AKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related stocks with our FREE daily email newsletter.